Literature DB >> 10530839

Osteosarcoma of the pelvis.

R J Grimer1, S R Carter, R M Tillman, D Spooner, D C Mangham, Y Kabukcuoglu.   

Abstract

Over a 25-year period we have treated 36 patients with osteosarcoma of the pelvis. Of the tumours, 24 (67%) were primary osteosarcomas and 12 (33%) arose either after irradiation or in association with Paget's disease. Six patients had a hindquarter amputation and 12 were treated by a limb-salvage procedure with intrapelvic excision. The five-year survival rate of all the patients with pelvic osteosarcoma was 18%, while for 17 treated by chemotherapy and surgery it was 41%. The prognosis for patients presenting with metastases or with secondary osteosarcoma was appalling and none survived after 29 months. No patient over the age of 50 years when seen initially survived for a year. Youth and a good response to chemotherapy along with complete surgical excision offer the best chance of cure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10530839     DOI: 10.1302/0301-620x.81b5.9241

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  21 in total

1.  Customised osteotomy guides and endoprosthetic reconstruction for periacetabular tumours.

Authors:  Boris Michael Holzapfel; Hakan Pilge; Peter Michael Prodinger; Andreas Toepfer; Susanne Mayer-Wagner; Dietmar Werner Hutmacher; Ruediger von Eisenhart-Rothe; Maximilian Rudert; Reiner Gradinger; Hans Rechl
Journal:  Int Orthop       Date:  2014-07       Impact factor: 3.075

2.  Carbon-ion radiotherapy of spinal osteosarcoma with long-term follow.

Authors:  Wei Zhang; Masato Tanaka; Yoshihisa Sugimoto; Tomoyuki Takigawa; Toshifumi Ozaki
Journal:  Eur Spine J       Date:  2015-08-23       Impact factor: 3.134

3.  Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents.

Authors:  Cristina Meazza; Roberto Luksch; Primo Daolio; Marta Podda; Alessandro Luzzati; Alessandro Gronchi; Antonina Parafioriti; Lorenza Gandola; Paola Collini; Andrea Ferrari; Michela Casanova; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Veronica Biassoni; Elisabetta Schiavello; Emilia Pecori; Maura Massimino
Journal:  Med Oncol       Date:  2014-02-21       Impact factor: 3.064

4.  Osteosarcoma of the pelvis: outcome analysis of surgical treatment.

Authors:  Bruno Fuchs; Nathan Hoekzema; Dirk R Larson; Carrie Y Inwards; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2008-10-15       Impact factor: 4.176

5.  [Chemotherapy-induced changes in high grade central osteosarcomas-experiences gained through the assignment as reference-pathologists of the COSS-studies].

Authors:  M Werner; G Delling
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

6.  Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.

Authors:  Claudia Blattmann; Susanne Oertel; Daniela Schulz-Ertner; Stefan Rieken; Sabine Haufe; Volker Ewerbeck; Andreas Unterberg; Irini Karapanagiotou-Schenkel; Stephanie E Combs; Anna Nikoghosyan; Marc Bischof; Oliver Jäkel; Peter Huber; Andreas E Kulozik; Jürgen Debus
Journal:  BMC Cancer       Date:  2010-03-12       Impact factor: 4.430

7.  Decancellation sacral osteotomy in iliosacral tumor resection: a technique for precise sacral margins.

Authors:  Yasser R Farid
Journal:  Clin Orthop Relat Res       Date:  2009-08-19       Impact factor: 4.176

8.  Oncologic and clinical outcomes in pelvic primary bone sarcomas treated with limb salvage surgery.

Authors:  G L Farfalli; J I Albergo; L E Ritacco; M A Ayerza; D L Muscolo; L A Aponte-Tinao
Journal:  Musculoskelet Surg       Date:  2015-08-05

9.  [Osteosarcoma of the pelvisTwo case reports and review of the literature].

Authors:  S Bading; E Mössinger; H Rosenthal; F Länger; L Bastian
Journal:  Unfallchirurg       Date:  2004-07       Impact factor: 1.000

10.  Rate and risk factors for wound complications after internal hemipelvectomy.

Authors:  Koichi Ogura; Patrick J Boland; Nicola Fabbri; John H Healey
Journal:  Bone Joint J       Date:  2020-03       Impact factor: 5.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.